Gozukucuk A, et al. - The present study was conducted to retrospectively compare the efficacy of desmopressin as monotherapy and desmopressin + oxybutynin as a combination therapy in the treatment of nocturnal enuresis. Between January 2014 and December 2019, 183 patients who applied to pediatrics, pediatrics surgery, and urology clinics with the complaint of nocturnal enuresis and diagnosed with primary monosymptomatic nocturnal enuresis were retrospectively assessed. Individuals were classified into two groups: (91 patients) who only received desmopressin therapy (Group 1), and those (92 patients) who received desmopressin and oxybutynin combination therapy (Group 2). For nocturnal enuresis, desmopressin is the only FDA- approved pharmacologic treatment. As per the findings, desmopressin decreases urine production and the anticholinergic agent allows the bladder to store more urine. Thus, for specially selected cases, combined therapy can be recommended in the monosymptomatic nocturnal enuresis treatment.